Andreessen Horowitz-backed Insitro, a machine-learning driven drug discovery and development company, completed the acquisition of Haystack Sciences, a company developing a platform to drive machine-learning enabled drug discovery through DNA-encoded libraries. Financial terms were not disclosed. “For the past two years, insitro has been building a company focused on the creation of predictive cell-based models of disease in order to enable the discovery of novel targets and evaluate the benefits of new or existing molecules in genetically defined patient segments. This acquisition enables us to expand our capabilities to the area of therapeutic design and advances us towards our goal of leveraging machine learning across the entire process of designing and developing better medicines for patients,” Daphne Koller, Ph.D., insitro Founder and CEO.